SEARCH

SEARCH BY CITATION

References

  • 1
    Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med 1980; 68: 74556.
  • 2
    Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, Dahiya R, Cardiff RD, Day ML, Cunha GR. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 2000; 60: 600817.
  • 3
    Wang Y, Sudilovsky D, Zhang B, Haughney PC, Rosen MA, Wu DS, Cunha TJ, Dahiya R, Cunha GR, Hayward SW. A human prostatic epithelial model of hormonal carcinogenesis. Cancer Res 2001; 61: 606472.
  • 4
    Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977; 37: 192933.
  • 5
    Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Up-regulation of TRPM-2, MMP-7 and ID-1 during sex hormone-induced prostate carcinogenesis in the Noble rat. Carcinogenesis 2001; 22: 96573.
  • 6
    Thompson CJ, Tam NN, Joyce JM, Leav I, Ho SM. Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in Noble rats and response to the antiestrogen ICI 182,780. Endocrinology 2002; 143: 2093105.
  • 7
    Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis 1995; 16: 13117.
  • 8
    Drago JR. The induction of NB rat prostatic carcinomas. Anticancer Res 1984; 4: 2556.
  • 9
    Wang YZ, Cunha GR, Hayward SW. In vitro and in vivo models of prostate cancer. In: CarrollPR GrossfeldGD, eds. American Cancer Society Atlas of Clinical Oncology. Hamilton, London: BC Decker Inc, 2002. 6881.
  • 10
    Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D, Gustafsson JA, Cunha G, Wong YZ. Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev Biol 2001; 229: 43242.
  • 11
    Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 1997; 138: 461321.
  • 12
    Lau KM, Leav I, Ho SM. Rat estrogen receptor-alpha and -beta, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. Endocrinology 1998; 139: 4247.
  • 13
    Prins GS. Developmental estrogenization of the prostate gland. In: NazRK, ed. Prostate: basic and clinical aspects. Boca Raton: CRC Press, 1997. 24566.
  • 14
    Prins GS, Marmer M, Woodham C, Chang W, Kuiper G, Gustafsson JA, Birch L. Estrogen receptor-beta messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology 1998; 139: 87483.
  • 15
    Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001; 159: 7992.
  • 16
    Cunha GR, Lung B. The possible influences of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J Exp Zool 1978; 205: 18194.
  • 17
    Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 33862.
  • 18
    Donjacour AA, Rosales A, Higgins SJ, Cunha GR. Characterization of antibodies to androgen-dependent secretory proteins of the mouse dorsolateral prostate. Endocrinology 1990; 126: 134354.
  • 19
    Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 500211.
  • 20
    Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transgenic models for the study of prostate cancer. Cancer 1993; 71: 116571.
  • 21
    McAlhany SJ, Ressler SJ, Larsen M, Tuxhorn JA, Yang F, Dang TD, Rowley DR. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res 2003; 63: 585965.
  • 22
    Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001; 166: 247283.
  • 23
    Hayward SWY, Cao M, Hom Y, Zhang B, Grossfeld G, Sudilovsky D, Cunha G. Malignant transformation in a non-tumorigenic human prostatic epithelial cell line. Cancer Res 2001; 61: 813542.
  • 24
    Belanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL, Labrie F. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994; 79: 108690.
  • 25
    Fisher D, Nelson J. Endocrine testing and treatment, 4th ed, vol. 3. Philadelphia: W.B. Saunders, 2001.
  • 26
    Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non- transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995; 31: 1424.
  • 27
    Hayward S, Rosen M, Haughney P, Cunha G. The human prostatic epithelial cell line BPH-1 recapitulates some key events of human prostatic development in tissue recombinations with rat urogenital sinus mesenchyme. Prostate 1996;( Suppl 6): 95.
  • 28
    Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 73744.
  • 29
    Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 138297.
  • 30
    Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4: 22338.
  • 31
    Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 343943.
  • 32
    Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998; 78: 31933.
  • 33
    Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003; 63: 388690.
  • 34
    Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998; 4: 8115.
  • 35
    Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002; 94: 1725.